LY 2300559Alternative Names: LY2300559; mGlu Pot/Cys - Eli Lilly
Latest Information Update: 07 Aug 2012
At a glance
- Originator Eli Lilly
- Class Antimigraines
- Mechanism of Action Leukotriene D4 receptor antagonists; Metabotropic glutamate receptor 2 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 16 Jul 2012 Discontinued - Phase-II for Migraine in Puerto Rico (PO)
- 16 Jul 2012 Discontinued - Phase-II for Migraine in USA (PO)
- 01 Apr 2012 Eli Lilly completes a phase II trial for Migraine prevention in USA and Puerto Rico (NCT01184508)